Devices Oncology

 News Release - February 7, 2006

North American Scientific Announces FDA Approval of New SurTrak(TM) Line of Brachytherapy Preloaded Needle Kits

Product Launch Scheduled For February 2006

CHATSWORTH, Calif.--(HSMN NewsFeed)--Feb. 7, 2006--North American Scientific, Inc. (Nasdaq:NASI ) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's application to market its new Prospera® SurTRAK line of brachytherapy products for the treatment of prostate cancer. The Company plans to launch the new line of brachytherapy products this month.

The new family of products includes the SurTRAK pre-plugged needle with a unique synthetic, micro-angled insert for improved seed delivery and precise placement. The SurTRAK(TM) strand, used in conjunction with the needle, is bio-resorbable and designed to hold the seeds at predetermined distances adding speed and precision to the prostate brachytherapy procedure. The new SurTRAK needle will also be available pre-loaded with seeds and spacers per the physician's prescription. The entire Prospera® SurTRAK(TM) family of products is available packed and sterile from the Company.

"The new SurTrak line is an important addition to our already proven line of high quality brachytherapy products, and we look forward to launching the product this month," said L. Michael Cutrer, President and Chief Executive Officer of North American Scientific. "Over the past few years we have seen increased demand for preloaded needles and the ability to strand to prescription, but we had previously used third party providers for these services. By integrating these valuable services into our product portfolio we believe we will be able to further strengthen and grow our brachytherapy business. The new SurTrak line should allow us to enhance delivery times to our customers and allow for better control of the order from start to finish." Mr. Cutrer concluded, "With the Prospera line of I-125 and Pd-103 brachytherapy seeds, our Precision Steppers and Stabilizers, and now our new SurTrak line, we can offer the medical community a broad line of high quality brachytherapy products for the treatment of prostate cancer."

About North American Scientific

North American Scientific is a leader in radiation therapy products and services in the fight against cancer. Its innovative products provide physicians with a set of tools for the treatment of various types of cancers. They include radioisotope-based brachytherapy seeds, used primarily in the treatment of prostate cancer, marketed under the trade name Prospera®; Intensity Modulated Radiation Therapy (IMRT); and Image Guided Radiation Therapy (IGRT). IMRT allows an escalated radiation dose to be delivered to a tumor while limiting exposure and damage to nearby healthy tissue. The Company's principal IMRT products are marketed under the trade names PEACOCK® and CORVUS. The Company's IGRT products, BAT®, BATCAM(TM) and nTRAK(TM) provide fast and accurate targeting and localization of a treatment volume on a daily basis. Over 500 hospitals and research sites worldwide are equipped with the Company's clinically proven PEACOCK, CORVUS (our proprietary treatment planning software), BAT, BATCAM and ancillary treatment solutions. Please visit www.nasmedical.com for more information.

Statements included in this release that are not historical facts may be considered forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company including, but not limited to, the impact of competitive products and pricing, technological changes, changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements, the ability of the Company to successfully directly market and sell its products, uncertainties relating to patent protection and regulatory approval, the stable supply of appropriate isotopes, research and development estimates, market opportunities, risks associated with strategic opportunities or acquisitions the Company may pursue and the risk factors included in the Company's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this news release speak only as of the date of this release, and the Company undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future results or otherwise.

Source: North American Scientific

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.